Rédaction Africa Links 24 with Damian Garde
Published on 2024-01-25 14:29:34
Get the latest updates and news on the science and politics driving biotech with our biotech newsletter. Good morning, everyone. Damian here with the current happenings in the world of biotech, including news about groundbreaking IPOs, the state of biotech venture capitalists, Gilead Sciences, and the quest for treatments for Parkinson’s disease.
Biotech company CG Oncology made headlines with their successful $380 million initial public offering, marking the first biotech IPO of 2024.
As the biotech industry faces financial challenges, venture capitalists are also feeling the pressure. With the industry experiencing a downturn, VCs are struggling to secure funding from large investment sources. Biotech VCs are navigating these difficult circumstances as they attempt to secure new funds to support drug companies.
Gilead Sciences has been focusing its efforts and investments on building a presence in the oncology sector, with mixed results. However, the company has seen success with their acquisition of Kite Pharma, a leader in CAR-T therapy. Looking forward, Gilead could stand to benefit from doubling down on their successful ventures in oncology, such as their partnership with Arcellx.
In the world of biotech IPOs, the potential public debut of obesity-related company Kallyope could inject much-needed capital into the sector. Kallyope’s novel approaches to treating obesity and type 2 diabetes through oral hormone-stimulating treatments have attracted investor interest.
Researchers have made progress in the quest for new treatments for Parkinson’s disease by mapping out the biological underpinnings of the condition. This work offers a framework for developing medicines that target the root causes of Parkinson’s, providing hope for the development of effective treatments.
In addition to these developments, we have highlighted other noteworthy reads in the biotech industry, including updates on pharma policing, legal issues, and limited drug availability.
If you’ve made it this far, don’t miss the opportunity to join our upcoming secret list for an exclusive biotech newsletter. Stay informed and stay ahead in the world of biotech with our comprehensive updates and insights.
Read the original article on Africa Health News
